Disease · MONDO_0010643
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Orca-T vs Standard of Care: deaths from any cause | 3 of 88 | 9 of 94 | 182 | NCT05316701 | Trial comparisons |
| Orca-T vs Standard of Care: serious adverse events | 34 of 88 | 53 of 94 | 182 | NCT05316701 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants With Graft Failure/Rejection | 2 of 66 | 5 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants Surviving by 1 Year | 51 of 66 | 47 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Patients With Non-relapse Mortality (NRM) | 7 of 66 | 6 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants Surviving up to 2 Years Without Disease Progression | 37 of 66 | 41 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Non-relapse Mortality | 8 of 66 | 10 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Incidence of Acute or Chronic Graft-versus-host Disease (GVHD) | 7 of 66 | 6 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Incidence of Clinically Significant Infections | 53 of 66 | 61 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants With Secondary Graft Failure | 0 of 66 | 0 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): The Number of Participants Alive at Two-years Follow up. | 50 of 66 | 44 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): deaths from any cause | 16 of 66 | 20 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Number of Participants With Acute Graft-versus-host Disease (GVHD) Grade II-IV by Day 100 | 36 of 66 | 37 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): Incidence of Relapse or Disease Progression | 17 of 66 | 11 of 64 | 130 | NCT00796068 | Trial comparisons |
| Arm I (Low Risk for Graft Failure) vs Arm II (High Risk for Graft Failure): serious adverse events | 27 of 66 | 23 of 64 | 130 | NCT00796068 | Trial comparisons |
| T Cell Depletion Transplant Participants vs Stem Cell Donors: deaths from any cause | 14 of 58 | 0 of 58 | 116 | NCT00378534 | Trial comparisons |
| T Cell Depletion Transplant Participants vs Stem Cell Donors: serious adverse events | 14 of 58 | 0 of 58 | 116 | NCT00378534 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants That Remained Disease-free Survival | 26 of 43 | 56 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Who Experienced Transplant Related Mortality | 5 of 43 | 4 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival | 17 of 43 | 48 of 57 | 100 | NCT00003838 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010643/comparisons